Facts
Radiation enteropathy severely affected the quality of life of cancer patients nowadays. Preclinical data suggest the pro-regenerative effects of mesenchymal stem cells on irradiated intestine. Epinal case report reveals the specific effectiveness of mesenchymal stem cells in managing pelvic radiotherapy-induced lesions in rectum and bladder lesions.
Open Questions
Due to most of radiation enteropathy patients are cancer survivors, is really that mesenchymal stem cells will initiate or promote their tumor growth? How to carry out a clinical trial for evaluating the therapeutic potentials of mesenchymal stem cells for radiation enteropathy? Will the mesenchymal stem cell-based therapy be an attractive tool for clinicians in managing radiation enteropathy patients in the future?
Radiotherapy is powerful in treating malignant tumors. According to the published data, at least 50% of cancer patients need radiotherapy during their treatment course, and approximately 25% of solid tumors undergo complete remission after radiotherapy. 1 However, damage to healthy tissue within the radiation field remains unavoidable. For abdominopelvic radiotherapy, the intestine is defined as an organ at risk (OAR). Herein, small intestine commonly presents acute injuries due to its high α / β ratio of >10 Gy according to linear-quadratic (L-Q) model. Besides, the estimated α / β ratio in rectum varies between 4.8 Gy and 5.4 Gy, commonly allowing for grade ≥2 toxicity happening. 2 , 3 Radiation-induced intestinal injuries/toxicities are known as radiation enteropathy (RE), which can be classified into two phases. Early RE commonly occurs within 3 months of radiotherapy, with an incidence of ~50%. 4 Late RE can be observed from 1 to 20 years post radiotherapy, with the incidence of 2–20%. 5 , 6 Several factors are involved in the development of late RE, including progressive cell loss and vascular obliteration in irradiated intestine, which will result in emergent or even fatal complications, such as obstruction, perforation, intestinal necrosis or acute hemorrhage. 6 , 7
Current clinical interventions for early RE mainly aim to relieve abdominal pain and diarrhea through spasmolysis and anti-edema drugs, maintaining electrolyte balance through conditional nutrient supplementation and alleviating inflammation or infection using antioxidants, glucocorticoids or antibiotics. 8 For late RE, lesioned intestine can be managed merely by surgery. 8 However, resection of diseased intestine appears to be not very effective, because the fibrogenesis in irradiated intestine could not be inhibited. Additionally, intestinal adhesion following surgery and dystrophia induced by removing a large portion of intestine adversely affect patient quality of life. 9 In recent years, the outcome from clinical studies exhibited the effectiveness of Pentoxifylline-Vitamin E in preventing intestinal fibrosis. 10 , 11 Meanwhile, several preclinical studies proposed some available agents for managing late RE, including ROCK inhibitor (Y-27632), 12 Pravastatin 13 and Simvastatin. 14 In addition to developing potential drugs, several preclinical studies were carried out for evaluating the therapeutic potentials of mesenchymal stem cells (MSCs) for RE.
MSCs, a population of undifferentiated cells deriving from early ectoderm and can be harvested from various tissues and organs. 15 MSCs can secret various types of growth factors, immune mediators and anti-fibrotic effectors, which are potent in mediating tissue regeneration. 16 , 17 , 18 And several clinical trials revealed the immunomodulatory benefits of MSCs in treating graft versus host disease (GVHD), inflammatory bowel disease (IBD), systemic lupus erythematosus (SLE) and arthritis. 19 , 20 , 21 , 22 Moreover, four patients, suffering from pelvic radiotherapy-induced injuries in rectum and in bladder, were successfully treated in Epinal Medical Center by using MSCs. 6 , 23 The effectiveness of MSCs lies in reducing abdominal pain, stanching rectal hemorrhage and healing fistula. 23 On this basis, we propose that managing RE patients by using MSCs will be an attractive therapeutic approach in the future.
In this review, we will build on evidence of an effect of MSCs on irradiated intestine by discussing the actions behind this effect, together with evidence relating to advances in anticancer therapy by using MSCs, to suggest the feasibility of MSCs in treating cancer patients with RE. At last, we will introduce the future efforts into carrying out MSC-related clinical trials for managing RE.
Potential Factors Involved in Pathogenesis of RE
Refractory lesions in the irradiated intestine develop through a lengthy process comprising multiple steps and contributory factors, although the mechanisms involving in RE pathogenesis remain unclear. Radiation-induced injuries refer to the histopathological changes in the epithelium and endothelium, where the oxidative stress and extended inflammation played a predominant role in leading to lesions, including ischemia, ulcer, necrosis or fibrosis. 24 , 25 In this section, current understanding on the pathogenesis of RE will be shared.
Epithelial event: Intestinal stem cell injury-induced de-epithelialization
The intestinal epithelium has a rapid self-renewal capacity, with a complete turnover time of ~96 h due to rapid cycling of cells within the crypts of Liberkühn. 26 The crypt base columnar (CBC) stem cells are responsible for maintaining homeostasis of intestinal epithelium by their producing progeny: transit-amplifying cells, which are committed into mature epithelial cells after 4–5 divisions ( Figure 1 ). 27 , 28
The CBC stem cells are radiosensitive. 29 It was reported that irradiation doses of at least 0.01 Gy are sufficient to result in apoptosis in 10% of CBC stem cells. 30 The pro-apoptotic effects of ionizing irradiation on CBC stem cells are dependent on their cell-cycle stage. 29 Ionizing irradiation will cause more DNA double-strand breaks (DSB) in G2/M phase than in G1/S phase. 31 The average dividing time of CBC cells is reported to be 21.5 h, which classifies them as rapid cycling and radiosensitive cells thereby. 32
Recent evidence suggested that the CBC stem cells are indispensable for epithelial regeneration upon being irradiated. 33 If the intestine receives the doses between 6 Gy and 12 Gy, CBC stem cells can be replenished by another pool of intestinal stem cells at the 4+ position of crypts. 34 , 35 Yet, if the irradiation doses are higher than 12 Gy, the CBC stem cells will rapidly die along with subsequent depletion of Paneth cells, who form the niches of CBC stem cells. 33 , 36 Together with the following processes, such as vascular damage-induced ischemia, oxidative stress and extended inflammation in irradiated sites, the milieus feeding CBC stem cells are further deteriorated, which even results in crypt death. 37 Ultimately, the barrier function of epithelium is lost thereby ( Figure 2 ).
Vascular event: endothelial injury-induced ischemia
The endothelial cells are primary targets of ionizing irradiation, and the apoptosis of endothelial cells accounts for the severity of lesions within irradiated intestine. 38 , 39 Evidence lie in that during the first 4 h after lethal irradiation, the apoptotic cells, most of which are positive for CD31, are mainly located in the laminar propria of the villi rather than the epithelial layer. 40 However, at 10 h post irradiation, numerous apoptotic cells are diffusely located in the epithelial layer from villi to crypt compartments rather than the laminar propira. 40 This switch of apoptosis from endothelial cells to epithelial cells indicates that injuries in irradiated intestinal cells are first occurred in endothelium. 39 , 40
After endothelial injury occurring, sub-endothelial extracellular matrix (ECM) components are exposed to platelets, which initiate hemostasis mechanisms by forming clots. 41 The coagulation cascade is hyperactivated by excessive secretion of von Willebrand factor (vWF) from injured endothelial cells, which results in vascular occlusion ultimately. 42 Then, vascular permeability will be increased, which leads to hyperemia or hemorrhage within injured sites. 43 As a result, the irradiated intestine has a poor blood supply ( Figure 2 ).
Inflammatory event: increasing oxidative stress and extending inflammation
The chemical reactions that reduce cell viability in irradiated tissues have been identified as excessive production of ROS, such as superoxide radicals and hydrogen peroxide, which derive from intracellular water oxidized by radiation energy and from mitochondria. 44 , 45 Under this condition, ROS can activate the signaling pathways leading to cell death in irradiated sites. 46 , 47 Following these processes, leucocytes roll to the damaged intestine in a short time for eliminating dead cells ( Figure 2 ). 48 , 49
Regarding the development of inflammation, current opinions believe that the molecular reactions in this process occur at sites extremely close to the vascular endothelium. 50 Upon endothelial apoptosis, pro-inflammatory effectors will be secreted for the recruitment of leucocytes recruitment to injured sites. 48 , 50 Herein, neutrophils are the first cells to adhere to endothelium and migrate to injured sites, where they eliminate dead cell debris for facilitating tissue repair. 41 , 48 , 49 , 51 However, the irradiated epithelium always leads to a reduced barrier function. 1 On this occasion, neutrophils also participate in eliminating large amounts of pathogens within the enteric cavity through secreting high levels of anti-pathogenic effectors, such as myeloperoxidase (MPO); 52 this process will increase the oxidative stress within injured intestine and reduce tissue regeneration thereby ( Figure 2 ). Meanwhile, upon exposure of injured tissues to pathogens, the cytotoxic T lymphocytes will eliminate the cells infected by these foreign stimuli through secreting cytolytic substances, such as perforin and granzymes, and through Fas/Fas ligand binding-induced apoptosis ( Figure 2 ). 53 , 54 Thus, the presence of pathogens promotes inflammation and induces a switch from an innate immune response to an adaptive immune response, 48 , 54 which has the inflammation extended in irradiated sites.
Neuroimmune event: interactions between mast cells and enteric neurons
The neuroimmune interactions between enteric neurons and mast cells formulate a network for controlling intestinal responses to ionizing irradiation, presenting the lesions of mucositis and fibrosis. 55 But the mast cells distinguish their contributions to the pathogenesis of RE. 55 Upon being irradiated, the mast cells within intestinal mucosa will be activated, presenting the release of some effectors, such as TNF- α and leukotriene (LT), for attracting neutrophils to clear bacteria-induced infection ( Figure 3 ). 55 Moreover, these activated mast cells will enhance TNF- α secretion by macrophages as well as macrophage-mediated fibrin deposition for coagulation ( Figure 3 ). 55 But for the mast cells in connective tissue, their contribution to RE is secreting some pro-fibrotic effectors, such as TGF- β 1, IL-4 and TNF- α ( Figure 3 ). 55 Although the exact mechanism by which neuroimmune interactions regulate the development of RE remains unknown, it is clear that the mediators from enteric sensory neurons, such as substance P and calcitonin gene-related peptide (CGRP), are critical for regulating the activation of mast cells. Herein, substance P is capable of amplifying the pro-inflammatory and pro-fibrotic responses of mast cells to ionizing irradiation through enhancing the secretions of histamine, TNF- α and TGF- β 1 by these cells, whereas the CGRP protects intestine against radiation-induced injuries ( Figure 3 ). 55 From this aspect, it is rational to propose that substance P is even important in deciding the severity of RE through activating mast cells.
Microbial event: dysbiosis post-irradiation
McLaughlin et al. 56 reported that the germ-free mice present radiation resistance comparing with conventional mice, indicating a potential link between the microbiota and host response to ionizing irradiation. As we are aware, the healthy gut contains nearly 300–500 bacterial species. 57 These commensal bacteria confer the intestine a barrier function, presenting persistent epithelial turnover and vigorous immunity. 57 For example, the NF- κ B signaling pathway in epithelial cells and some intestine-specific immune cells will be activated upon the interactions between their toll-like receptors and luminal bacteria, which stimulate the epithelial proliferation as well as lead to immune tolerance of intestine to foreign antigens. 58 However, when the epithelium loses its integrity post-irradiation, the commensal bacteria will transmigrate into intestinal tissue, functioning as bioterrorists for even triggering sepsis. 57 , 58 In this context, dysbiosis commonly occurs. Manichanh et al. 59 reported that the bacterial constitution of feces is altered after the patients receiving pelvic radiotherapy, presenting the increased clusters of Bacilli and Actinobacteria, whereas decreasing in clostridial cluster. Besides, previous data indicated that the microbiota confer the intestinal endothelium and lymphocyts radiation sensitivity, which is linked to the suppression of fasting-induced adipose factor by luminal microbiota. 60 To a certain extent, this finding corresponds to that endothelial injuries are the primary lesions of RE. 40 In current opinions, the interactions between the microbiota and host regulate the intestinal responses to ionizing irradiation, and not all intestinal bacteria promote pathogenesis of RE. 57 , 58 For example, the microbiota can induce epithelial expression of nucleotide-binding oligomerization domain-containing protein 2 (NOD-2) against ischemia/reperfusion-induced hypoxic stress and autophagy, 61 indicating the bacteriotherapy for RE is also promising. 62
Fibrotic event: fibrogenesis after tissue injuries
Radiation-induced injuries in epithelium and endothelium have a central role in initiating intestinal fibrosis, which can be promoted by the extended inflammation within injured sites. 24 , 25 Upon epithelial injuries, irradiated intestine will reduce its barrier functions. 1 On this occasion, the innate immune cells, such as macrophages and dendritic cells (DCs), will be activated by pathogens in enteric cavity, leading to secretion of pro-inflammatory cytokines, such as TNF- α , IL-1, IL-4 and IL-8. 63 These cytokines activate some adaptive immune cells, such as Th2 and Th17 cell, which separately secrete IL-13 and IL-17 for promoting tissue remodeling ( Figure 2 ). 41 , 63 Upon endothelial injuries, the blood vessels will increase their permeability, enabling recruitment of pro-inflammatory cells to injured sites. 41 Among these infiltrated cells, the monocyte-macrophage system is reported to facilitate fibrosis through secreting PDGF, CTGF and TGF- β 1, allowing for fibroblast-myofibroblast transition, myofibroblast proliferation and ECM deposition at injured sites ( Figure 2 ). 64 , 65
Stem Cell-Based Regenerative Therapy for Rodent Models of RE
In the past decade, extensive efforts have been made in stem-cell based therapy for rodent models of RE ( Table 1 ).
The therapeutic effects of MSCs on RE
To our knowledge, the first study was performed by Sémont et al. 66 Their data showed that human MSCs exhibited potentials for maintaining the integrity of irradiated intestine. 66 After MSC intervention, the irradiated mice survived longer than controls, and the epithelium showed hypertrophic villi, comprising increased numbers of proliferative cells and fewer apoptotic cells in the crypts. In addition, the newborn villus maintained its absorptive function via normal levels of Na + -K + -ATPase expression. 67 Similarly, Kudo et al. 68 reported that MSCs could extend the life span of irradiated mice, which was distinct from their previous data by using embryonic stem cells (ESCs) transplantation. 69 Regarding the repair actions by MSCs, Saha et al. 70 reported that MSCs could protect irradiated intestine by increasing serum levels of R-spondin1, KGF, IL-10 and PGE2, which function as effectors for promoting proliferation and inhibiting both apoptosis and inflammation within irradiated intestine. Besides, MSCs were capable of promoting epithelial regeneration using their secretion of IL-6. 71 Moreover, the MSC-conditioned medium also exhibited the pro-regenerative potentials for irradiated epithelium. 72 Besides, we found that MSC infusion could accelerate neovascularization within irradiated sites by triggering the intrinsic repair action of upregulated expressions of SDF-1, VEGF, basic FGF and Flk-1. 73 Afterwards, by using a pig model of radiation proctitis, Linard et al. 74 reported that repeated autologous transplantation of MSCs could counter act the inflammation in rectal mucosa by increasing host IL-10 production, and protect rectum against radiation-induced fibrosis by reducing local Col1a2/Col3a1 and TGF- β /CTGF expression and altering the matrix metalloproteinase (MMP)-tissue inhibitor of metalloproteinase (TIMP) balance as well. Similarly, based on using a rat model of radiation proctitis, Bessout et al. 75 reported that autologous transplantation of MSCs was capable of mitigating the aberrant inflammation in the colorectal mucosa by elevating the local levels of glucocorticoid, which would inhibit the proliferation and induce apoptosis in radiation-activated T cells. These preclinical studies indicate that MSC-based therapy is potent for repairing the lesions associated with RE. Especially for using heterogenic MSCs, the host repair can be triggered as well, attributing to the autocrine/paracrine actions achieved by MSCs.
The MSC-based gene therapy for RE
The chemotactic properties of MSCs enable themselves to be used as delivery vehicles for the targeted secretion of tissue repair factors at injured sites. Herein, several lines of evidence showed that radiation-induced upregulation in CXCL12 expression is important for the homing of MSCs to injured sites through the interaction between CXCR4 and CXCL12. 76 , 77 , 78 For improving the homing efficacy of MSCs toward irradiated intestine, Zhang et al. 79 established the MSCs, overexpressing CXCR4 gene, and found that the restoration of epithelial integrity was accelerated upon intervention by CXCR4 gene-modified MSCs. In another study, Yang et al. 80 reported that manganese superoxide dismutase (MSD) gene-modified MSCs were more effective than control MSCs in reducing mortality of irradiated mice, relieving gastrointestinal symptoms and restoring epithelial integrity with a spot of apoptotic cells in irradiated mice. Moreover, Hu et al. 81 revealed that MSCs overexpressing Trx-1 gene were powerful in reducing oxidative stress in the irradiated intestine. Overall, the superior effectiveness of gene-modified MSCs over unmodified MSCs in healing RE can be attributed to the dual therapeutic effects of the high expression of ectopic genes and the intrinsic functions of MSCs.
Putative Actions Involved in RE Resolution by MSC Infusion
At present, the mechanisms involved in the repair of irradiated intestine by MSCs are still not fully investigated. But according to recent advances, we suggest several putative actions of RE management achieved by MSCs. In our opinion, the putative actions by which MSCs repair RE can be summarized as follows ( Figure 4 ). Primarily, the engrafted MSCs induce infiltrated immune cells to switch from pro-inflammatory to anti-inflammatory cytokine secretion, resulting in milieus that promote anti-inflammatory events. As a secondary effect, repair responses are boosted by systemic events, such as elevated levels of regenerative facilitators, despite the rapid disappearance of donor MSCs. 82 Thus, benign cytokine milieus cause regeneration of the injured intestine to be accelerated.
Step 1: homing to injured sites
Homing of infused MSCs to injured sites can be regarded as a prerequisite. According to recent data, several events mediated this homing process, such as CXCR1/2-CXCL8, CXCR4-CXCL12, CX 3 CR1-fractalkine, CCR7-CCL21 and ICAM-1/VCAM-1. 77 , 83 , 84 , 85 Upon these molecular bindings, MSCs first adhere to the endothelium, forming a defensive barrier against pathogens together with the pre-existing pericytes. 86 The foreign MSCs then migrate to the laminar propria, where they perform pro-regenerative functions. 87
Step 2: interacting with immune cells and bacteria
Cytokines secreted by both immune cells and MSCs mediate crosstalk among these cell types through regulatory feedback mechanisms, termed as ‘Educational action' of MSCs ( Figure 5 ). 17 The engrafted MSCs will alter the inflammatory milieus through interacting with infiltrated immune cells via secretion central immune mediators, including IL-10, PGE2, iNOS, IDO and HLA-G5. 17 For example, in a co-culturing system, BM-MSC increases the IL-10 secretion and decreases the TNF- α secretion in DCs; reduces IFN- γ secretion in Th1 cells and natural killer (NK) cells, and increases IL-4 secretion in Th2 cells. 88 Under the same conditions, macrophages increase IL-10 and IL-12p40 secretion, while reducing TNF- α , IFN- γ , IL-6 and IL-12p70 secretion. 89 These effects have also been observed in vivo : Németh et al. 90 found that MSC infusion-induced elevation of host PGE2 has a central role in enhancing IL-10 synthesis by monocytes and macrophages from the lungs of septic mice, while reducing IL-12 secretion from these immune cells. These events inhibited neutrophil infiltration and IL-12-induced activations of both NK cells and cytotoxic T lymphocytes. 90 , 91
In addition to the antagonistic effects of MSCs on immune cell pro-inflammatory profiles, the MSCs can inhibit the proliferation of effective T lymphocytes through secreting iNOS or HLA-G5, inhibiting DC maturation using PGE2, and inhibiting NK-mediated cytolysis and NK proliferation using PGE2, HLA-G5 or IDO ( Figure 5 ). 92 , 93 , 94 In contrast to their anti-proliferative effects on such immune cells, MSCs will stimulate proliferation of regulatory T cells (Tregs) via secreting HLA-G5 and PGE2 ( Figure 5 ). 94 , 95 Recent in vivo data also confirmed that MSC infusion can increase the Treg number in mice with colitis; this increase is dependent on MSCs migrating to the spleen and interacting with splenic CD11b + innate immune cells. 96 , 97 But for radiation proctitis, current opinion on whether IL-10 and/or Tregs participate in suppressing mucosal inflammation seems to be contradictive. A previous study found that the antagonistic effect of MSCs on the inflammation in colorectal mucosa of rat exhibited the IL-10/Treg-independent manner, which is opposite to the finding by using a pig model. 74 , 75 In spite of similar strategies in establishing animal models of radiation proctitis and carrying out autologous transplantation, the mechanism by which MSCs mitigate intestinal inflammation probably varies among species. In addition, the following issues, including delivery times and doses of MSCs, appear to affect the host responses in clearing systemic or local inflammation.
As described above, neuroimmune interactions and dysbiosis contribute to the pathogenesis of RE. Fortunately, recent data suggested that MSCs antagonized the activation of mast cells by secreting PGE2 and TGF- β 1, leading to decreased degranulation, reduced ability of chemotaxis and reduced release of TNF- α by mast cells ( Figure 5 ). 98 , 99 Moreover, accumulative evidence suggest that human MSCs are powerful in protecting against Gram-negative bacteria-induced sepsis, relying on their secretions of LL-37, IDO and heme oxygenase-1 (HO-1), and strengthening the phagocytosis by neutrophils and macrophages as well ( Figure 5 ). 100 , 101 , 102 , 103
Step 3: amplification of intrinsic repair
To date, it is still difficult to define the extent to which allogenic/heterogenic MSCs contribute to tissue regeneration, because immune rejection driven by recipient CD4 + and/or CD8 + T lymphocytes and oxidative stress within injured areas were reported to limit viability of infused MSCs. 82 , 104 But relatively few ectopic MSCs can lead to excellent therapeutic effects on injured host tissues that have a lost a large number of functional cells. A previous study reported that enhanced tissue repair achieved despite donor MSCs being rapidly eliminated after transplantation. 105 From this point, we conclude that MSCs act as facilitators via triggering and boosting systemic repair responses. In spite of no consensus on whether the anti-inflammatory effect of MSCs on irradiated rectum of IL-10 and/or Treg involvment, reduced inflammation is always achieved after infusion of MSCs. 74 , 75 Combining with the actions of MSCs in clearing bacteria and minimizing the activation of mast cells, benign milieus for tissue regeneration are established, which will be beneficial to attract host bone marrow progenitors for reconstructing the niches of CBC stem cells and building on vasculature. 106 , 107 On this basis, by using the assistances from locally upregulated mitotic facilitators, 70 , 83 re-epithlialization and angiogenesis/neovascularization in the injured intestine are accelerated thereby.
Step 4: post-regeneration reversion of tissue homeostasis
When the neo-formed epithelium or endothelium is restored to its normal size and structure, p53-mediated cell-cycle arrest halts cell proliferation and prevents tissue hypertrophy. Levels of cytokine or hormone secretion are altered in the host tissue to maintain physiological epithelial homeostasis. 108 , 109 This process provides an adequate blood supply to the gut, eliminates inflammation and prevents fibrosis from developing in the irradiated intestine.
MSC and Cancer: A Latent Factor Affecting Security of MSCs for RE
The clinical responses of four Epinal patients to MSC-based therapy preliminarily revealed the specific roles of MSCs in treating pelvic radiotherapy-induced injuries in rectum and in bladder. 6 , 23 Although no evidence indicating the relapses in their prostate cancers after MSC intervention, 23 the debate over whether MSCs promote the growth and metastasis of cancer cells or initiate new cancers persists for a long time, because truth lies in that majority of RE patients are still cancer survivors. 110
‘Negative effects' of MSCs on tumor growth and their oncogenicity
Unrestricted cancer cell proliferation is largely driven by dysregulated growth signals originating from mutated genes. 110 Some researchers believe that MSC-initiated immune suppression, immune cell dysfunction, cell division and angiogenesis could promote cancer progression. 111 , 112 In addition, MSCs would undergo spontaneous malignant transformation during a culture period of 105 weeks. 113 , 114 , 115 Genomic instability, such as spontaneous p53 mutation in aged or in p21-deficient MSCs, was related to fibrosarcoma formation in vivo . 114 , 115 , 116 , 117 By contrast, the risk of genetic mutations or cell aging could be minimized, if MSCs are cultured for less than 16 weeks. 118 , 119
‘Positive effects' of MSCs on tumor growth and their anticancer potential
Recent data also suggested that MSCs exhibited potentials for inhibiting tumor growth through arresting cell cycling and activating signaling pathways related to cell death ( Table 2 ). 120 , 121 , 122 , 123 , 124 , 125 , 126 , 127 , 128 , 129 , 130 , 131 , 132 , 133 For example, human adipose MSCs could inhibit tumor cell expansion via secreting Dickkopf-related protein 1, a Wnt signaling antagonist. 134 , 135 , 136 Another anticancer activity of MSCs involved the blockade of PI3K/Akt signaling pathway, leading to increased levels of cell-death related molecules, while decreased levels of cell survival-related molecules ( Table 2 ). 121 , 133 , 137
In addition, MSC-based gene therapy for various solid tumors improves host anticancer responses through releasing the foreign gene-encoded proteins, such as iNOS, IL-2 and IL-12. 138 , 139 , 140 Optimistically, some clinical trials for evaluating the specific potentials of MSCs on treating cancer and cancer regimen-related disorders are being carried out ( ClinicalTrials.gov data). Relevant results will be referred for anticipating the potential risks related to MSC-based therapy.
Future Efforts into MSC-Based Therapy for RE Patients
Because of the success in treating Epinal patients by using MSCs, a new protocol for treating late severe damages of abdominal radiotherapy has been performed in Epinal Medical Center since 2013. 141 Certainly, the ‘Epinal experiences' will deserve being referred worldwide in the future. If so, then MSC-based therapy is merely an attractive tool in managing RE patients. And clinical use of MSCs should focus on the following rules: (i) Ensuring the quality control of MSCs, including the processes for generating MSCs, identifying MSCs, detecting pathogens and endotoxin, and removing residual supplements. 142 A detailed protocol for generating clinical grade human MSCs can be consulted, 143 if using autologous MSCs. If using allogenic MSCs, then some FDA-approved products are available nowadays. But when allogenic MSCs are poorly tolerated, MSC exosomes are expected to become alternative candidates for managing RE. First, MSC exosomes show the potentials in mediating tissue regeneration because they contain a broad spectrum of bioactive substance. 144 For example, the adenylate kinase and nucleoside-diphosphate kinase within exosomes are critical in increasing ATP production within injured cells. 144 Additionally, CD73 molecules presenting in MSC exosomes are capable of hydrolyzing AMP into adenosine, an activator for cell survival by stimulating MAPK and PI3K/Akt signaling pathways. 144 Moreover, MSC exosomes contain more than 200 immunomodulatory proteins, which confer the anti-inflammatory capability on exosomes. 144 Second, the MSC exosomes seem to be stable in vitro, because their integrities and sizes were seldom affected by repeated freezing-thawing, 145 allowing single extraction of exosomes for multiple administrations clinically. (ii) Formulating a protocol for MSC therapy for RE, including the delivery route of MSCs, timing and frequency of injection, the optimal dose and passage. 146 (iii) Making countermeasure against possible complications or emergencies related to MSC infusion, such as fever, allergy or even shock. 142 , 147 (iv) Establishing the criteria for evaluating the effectiveness achieved by MSC infusion in RE resolution, which somewhat guarantees the researchers avoid overstating the positive outcomes. 148 , 149 , 150
Conclusions
Overall, data from preclinical study and Epinal case report highlight the essentiality of futuristic use of MSCs in RE management. MSC-based therapy is expected to have beneficial effects on the quality of life of RE patients.
This study was funded by the National Natural Science Funds of China (Grant: 81372929).
crypt base columnar
calcitonin gene-related peptide
dendritic cell
double-strand break
extracellular matrix
fecal inconvenience
graft versus host disease
heme oxygenase-1
inflammatory bowel disease
leukotriene
radiation enteropathy
systemic lupus erythematosus
toll-like receptor
matrix metalloproteinase
myeloperoxidase
mesenchymal stem cell
manganese superoxide dismutase
neutropenic enterocolitis
nuclear factor-kappa B
nucleotide-binding oligomerization domain-containing protein 2
organ at risk
tissue inhibitor of metalloproteinase
regulatory T cell
von Willebrand factor
Edited by D Aberdam
The authors declare no conflict of interest.
Hauer-Jensen M Denham JW Andreyev HJ Radiation enteropathy-pathogenesis, treatment and prevention Nat Rev Gastroenterol Hepatol 2014 11 470 479 10.1038/nrgastro.2014.46 PMC4346191 24686268
Tucker SL Thames HD Michalski JM Bosch WR Mohan R Winter K Estimation of α / β for late rectal toxicity based on RTOG 94-06 Int J Radiat Oncol Biol Phys 2011 81 600 605 21377288 10.1016/j.ijrobp.2010.11.080 PMC3163802
Brenner DJ Fractionation and late rectal toxicity Int J Radiat Oncol Biol Phys 2004 60 1013 1015 15519768 10.1016/j.ijrobp.2004.04.014
Kennedy GD Heise CP Radiation colitis and proctitis Clin Colon Rectal Surg 2007 20 64 72 20011363 10.1055/s-2007-970202 PMC2780150
Andreyev HJ Davidson SE Gillespie C Allum WH Swarbrick E Practice guidance on the management of acute gastrointestinal problems arising as a result of treatment for cancer Gut 2012 61 179 192 22057051 10.1136/gutjnl-2011-300563 PMC3245898
Chaple A Francois S Douay L Benderitter M Voswinkel J New insights for pelvic radiation disease treatment: multipotent stromal cell is a promise mainstay treatment for the restoration of abdominopelvic severe chronic damages induced by radiotherapy World J Stem Cells 2013 5 106 111 24179599 10.4252/wjsc.v5.i4.106 PMC3812515
Gilbert JD Byard RW Fatal ischemic enteritis with hemorrhage-a late complication of treated Wilms tumor J Forensic Sci 2013 58 234 236 22924338 10.1111/j.1556-4029.2012.02264.x
Sarin A Safar B Management of radiation proctitis Gastroenterol Clin North Am 2013 42 913 925 24280407 10.1016/j.gtc.2013.08.004
Spinelli A Correale C Szabo H Montorsi M Intestinal fibrosis in Crohn's disease: medical treatment or surgery Curr Drug Targets 2010 11 242 248 19916949 10.2174/138945010790309984
Gothard L Cornes P Brooker S Earl J Glees J Hall E Phase II study of vitamin E and pentoxifylline in patients with late side effects of pelvic radiotherapy Radiother Oncol 2005 75 334 341 16086914 10.1016/j.radonc.2005.02.002
Hamama S Delanian S Monceau V Vozenin MC Therapeutic management of intestinal firbosis induced by radiation therapy: from molecular profiling to new intervention strategies et vice et versa Fibrogenesis Tissue Repair 2012 5 S13 23259677 10.1186/1755-1536-5-S1-S13 PMC3368760
Bourgier C Haydont V Milliat F Francois A Holler V Lasser P Inhibition of Rho kinase modulates radiation induced fibrogenic phenotype in intestinal smooth muscle cells through alteration of the cytoskeleton and connective tissue growth factor expression Gut 2005 54 336 343 15710979 10.1136/gut.2004.051169 PMC1774418
Haydont V Bourgier C Pocard M Lusinchi A Aigueperse J Mathé D Pravastatin Inhibits the Rho/CCN2/extracellular matrix cascade in human fibrosis explants and improves radiation-induced intestinal firbosis in rats Clin Cancer Res 2007 13 5331 5340 17875761 10.1158/1078-0432.CCR-07-0625
Wang J Boerma M Fu Q Kulkarni A Fink LM Hauer-Jensen M Simvastatin ameliorates radiation enteropathy development after localized, fractionated irradiation by a protein C-independent mechanism Int J Radiat Oncol Biol Phys 2007 68 1483 1490 17674978 10.1016/j.ijrobp.2007.03.036 PMC2000701
Jiang Y Jahagirdar BN Reinhardt RL Schwartz RE Keene CD Ortiz-Gonzalez XR Pluripotency of mesenchymal stem cells derived from adult marrow Nature 2002 418 41 49 12077603 10.1038/nature00870
Park BS Kim WS Choi JS Kim HK Won JH Ohkubo F Hair growth stimulated by conditioned medium of adipose-derived stem cells is enhanced by hypoxia: evidence of increased growth factor secretion Biomed Res 2010 31 27 34 20203417 10.2220/biomedres.31.27
Yagi H Soto-Gutierrez A Parekkadan B Kitagawa Y Tompkins RG Kobayashi N Mesenchymal stem cells: mechanisms of immunomodulation and homing Cell Transplant 2010 19 667 679 20525442 10.3727/096368910X508762 PMC2957533
Singh S Saraiva L Elkinton PT Friedland JS Regulation of matrix metalloproteinase-1,-3 and -9 in Mycobaterium tuberculosis-dependent respiratory networks by the rapamycin-sensitive PI3K/p70(S6K) cascade FASEB J 2014 28 85 93 24076964 10.1096/fj.13-235507
Newell LF Deans RJ Maziarz RT Adult adherent stromal cells in the management of graft-versus-host disease Expert Opin Biol Ther 2014 14 231 246 24397853 10.1517/14712598.2014.866648
Wang D Li J Zhang Y Zhang M Chen J Li X Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical study Arthritis Res Ther 2014 16 R79 24661633 10.1186/ar4520 PMC4060570
Koh YG Choi YJ Intrapatellar fat pad-derived mesenchymal stem cell therapy for knee osteoarthritis Knee 2012 19 902 907 22583627 10.1016/j.knee.2012.04.001
Herreros MD Garcia-Arranz M Guadalajara H De-La-Quintana P Garcia-Olmo D FATT Collaborative Group Autologous expanded adipose-derived stem cells for the treatment of complex cryptoglandular perianal fistulas: a phase III randomized clinical trial (FATT 1: fistula Advanced Therapy Trial 1) and long-term evaluation Dis Colon Rectum 2012 55 762 772 22706128 10.1097/DCR.0b013e318255364a
Voswinkel J Francois S Simon JM Benderitter M Gorin NC Mohty M Use of mesenchymal stem cells (MSCs) in chronic inflammatory fistulizing and fibrotic diseases: a comprehensive review Clin Rev Allergy Immunol 2013 45 180 192 23296948 10.1007/s12016-012-8347-6
Langberg CW Sauer T Reitan JB Hauer-Jensen M Relationship between intestinal fibrosis and histopathologic and morphometric changes in consequential and late radiation enteropathy Acta Oncol 1996 35 81 87 8619945 10.3109/02841869609098484
Latella G Di Gregorio J Flati V Rieder F Lawrence IC Mechanisms of initiation and progression of intestinal fibrosis in IBD Scand J Gastroenterol 2015 50 53 65 25523556 10.3109/00365521.2014.968863
Umar S Intestinal stem cells Curr Gastroenterol Rep 2010 12 340 348 20683682 10.1007/s11894-010-0130-3 PMC2965634
Sato T Vries RG Snippert HJ van de Wetering M Barker N Stange DE Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche Nature 2009 459 262 265 19329995 10.1038/nature07935
van der Flier LG Clevers H Stem cells, self-renewal, and differentiation in the intestinal epithelium Annu Rev Physiol 2009 71 241 260 18808327 10.1146/annurev.physiol.010908.163145
Ishizuka S Martin K Booth C Potten CS de Murcia G Bürkle A Poly(ADP-ribose) polymerase-1 is a survival factor for radiation-exposed intestinal epithelial stem cells in vivo Nucleic Acids Res 2003 31 6198 6205 14576306 10.1093/nar/gkg840 PMC275480
Zhu Y Huang YF Kek C Bulavin DV Apoptosis differently affects lineage tracing of Lgr5 and Bmi1 intestinal stem cell populations Cell Stem Cell 2013 12 298 303 23415913 10.1016/j.stem.2013.01.003
Frankenberg-Schwager M Gebauer A Koppe C Wolf H Pralle E Frankenberg D Single-strand annealing, conservative homologous recombination, nonhomologous DNA end joining, and the cell cycle-dependent repair of DNA double-strand breaks induced by sparsely or densely ionizing radiation Radiat Res 2009 171 265 273 19267553 10.1667/RR0784.1
Schepers AG Vries R van den Born M van de Wetering M Clevers H Lgr5 intestinal stem cells have high telomerase activity and randomly segregate their chromosomes EMBO J 2011 30 1104 1109 21297579 10.1038/emboj.2011.26 PMC3061032
Metcalfe C Kljavin NM Ybarra R de Sauvage FJ Lgr5+ stem cells are indispensible for radiation-induced intestinal regeneration Cell Stem Cell 2014 14 149 159 24332836 10.1016/j.stem.2013.11.008
Sangiorgi E Capecchi MR Bmi1 is expressed in vivo in intestinal stem cells Nat Genet 2008 40 915 920 18536716 10.1038/ng.165 PMC2906135
Montgomery RK Carlone DL Richmond CA Farilla L Kranendonk ME Henderson DE Mouse telomerase reverse transcriptase (mTert) expression marks slowly cycling intestinal stem cells Proc Natl Acad Sci USA 2011 108 179 184 21173232 10.1073/pnas.1013004108 PMC3017192
Sato T van Es JH Snippert HJ Stange DE Vries RG van den Born M Paneth cells constitute the niche for Lgr5 stem cells in intestinal crypts Nature 2011 469 415 418 21113151 10.1038/nature09637 PMC3547360
Gilbert S Nivarhi H Mayhew CN Lo YH Noah TK Vallance J Activated STAT5 confers resistance to intestinal injury by increasing intestinal stem cell proliferation and regeneration Stem Cell Reports 2015 4 209 225 25579133 10.1016/j.stemcr.2014.12.004 PMC4325270
Ungvari Z Podlusky A Sosnowska D Tucsek Z Toth P Deak F Ionizing radiation promotes the acquisition of a senescence-associated secretory phenotype and impairs angiogenic capacity in cerebromicrovascular endothelial cells: role of increased DNA damage and decreased DNA repair capacity in microvascular radiosensitiivity J Gerontol A Biol Sci Med Sci 2013 68 1443 1457 23689827 10.1093/gerona/glt057 PMC3814240
Abderrahmani R Francois A Buard V Tarlet G Blirando K Hneino M PAI-1-dependent endothelial cell death determines severity of radiation-induced intestinal injury PLoS One 2012 7 e35740 22563394 10.1371/journal.pone.0035740 PMC3338537
Paris F Fuks Z Kang A Capodieci P Juan G Ehleiter D Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice Science 2001 293 293 297 11452123 10.1126/science.1060191
Wynn TA Integrating mechanisms of pulmonary fibrosis J Exp Med 2011 208 1339 1350 21727191 10.1084/jem.20110551 PMC3136685
Giblin JP Hewlett LJ Hannah MJ Basal secretion of von Willebrand factor from human endothelial cells Blood 2008 112 957 964 18344423 10.1182/blood-2007-12-130740
Kopaniak MM Issekutz AC Movat HZ Kinetics of acute inflammation induced by E coli in rabbits. Quantitation of blood flow, enchanced vascular permeability, hemorrhage, and leukocyte accumulation Am J Pathol 1980 98 485 498 6986785 PMC1903407
Nikjoo H O'Neill P Terrissol M Goodhead DT Modelling of radiation-induced DNA damage: the early physical and chemical event Int J Radiat Biol 1994 66 453 457 7983431 10.1080/09553009414551451
Hill S Van Remmen H Mitochondrial stress signaling in longevity: A new role for mitochondrial function in aging Redox Biol 2014 2 936 944 25180170 10.1016/j.redox.2014.07.005 PMC4143811
Martindale JL Holbrook NJ Cellular response to oxidative stress: signaling for suicide and survival J Cell Physiol 2002 192 1 15 12115731 10.1002/jcp.10119
Almeida AS Figueiredo-Pereira C Vieira HL Carbon monoxide and mitochondria-modulation of cell metabolism, redox response and cell death Front Physiol 2015 6 33 25709582 10.3389/fphys.2015.00033 PMC4321562
Mittal M Siddigui MR Tran K Reddy SP Malik AB Reactive oxygen species in inflammatory and tissue injury Antioxid Redox Signal 2014 20 1126 1167 23991888 10.1089/ars.2012.5149 PMC3929010
Johnson LB Riaz AA Adawi D Wittgren L Bäck S Thornberg C Radiation enteropathy and leucocyte-endothelial cell reactions in a refined small bowel model BMC Surg 2004 4 10 15363103 10.1186/1471-2482-4-10 PMC522820
Rao RM Yang L Garcia-Cardena G Luscinskas FW Endothelial-dependent mechanisms of leukocyte recruitment to the vascular wall Circ Res 2007 101 234 247 17673684 10.1161/CIRCRESAHA.107.151860b
Kolaczkowska E Kubes P Neutrophil recruitment and function in health and inflammation Nat Rev Immunol 2013 13 159 175 23435331 10.1038/nri3399
Reumaux D de Boer M Meijer AB Duthilleul P Roos D Expression of myeloperoxidase (MPO) by neutrophils is necessary for their activation by anti-neutrophil cytoplasm autoantibodies (ANCA) against MPO J Leukoc Biol 2003 73 841 849 12773517 10.1189/jlb.1102567
Wonderlich J Shearer G Livingstone A Brooks A Induction and measurement of cytotoxic T lymphocyte activity Curr Protoc Immunol 2006 Chapter 3 Unit 3.11. 10.1002/0471142735.im0311s72 18432971
Kugelberg E Pattern recognition receptors: curbing gut inflammation Nat Rev Immunol 2014 14 583 25132096 10.1038/nri3735
Wang J Hauer-Jensen M Neuroimmune interactions: potential target for mitigating or treating intestinal radiation injury Br J Radiol 2007 1 S41 S48 17704325 10.1259/bjr/33057885
McLaughlin MM Dacquisto MP Jacobus DP Horowitz RE Effects of the germfree state on responses of mice to whole-body irradiation Radiat Res 1964 23 333 349 14229117
Ferreira MR Muls A Dearnaley DP Andreyev HJ Microbiota and radiation-induced bowel toxicity: lesions from inflammatory bowel disease for the oncologist Lancet Oncol 2014 15 e139 e147 24599929 10.1016/S1470-2045(13)70504-7
Packey CD Ciorba MA Microbial influences on the small intestinal response to radiation injury Curr Opin Gastroenterol 2010 26 88 94 20040865 10.1097/MOG.0b013e3283361927 PMC4063200
Manichanh C Varela E Martinez C Antolin M Liopis M Doré J The gut microbiota predispose to the pathophysiology of acute postradiotherapy diarrhea Am J Gastroenterol 2008 103 1754 1761 18564125 10.1111/j.1572-0241.2008.01868.x
Crawford PA Gordon JI Microbial regulation of intestinal radiosensitivity Proc Natl Acad Sci USA 2005 102 13254 13259 16129828 10.1073/pnas.0504830102 PMC1193536
Perez-Chanona E Mühlbauer M Jobin C The microbiota protects against ischemia/reperfusion-induced intestinal injury through nucleotide-binding oligomerization domain-containing protein 2 (NOD2) signaling Am J Pathol 2014 184 2965 2975 25204845 10.1016/j.ajpath.2014.07.014 PMC4215024
Ciorba MA Stenson WF Probiotic therapy in radiation-induced intestinal injury and repair Ann NY Acad Sci 2009 1165 190 194 19538306 10.1111/j.1749-6632.2009.04029.x PMC4063203
Lawrance IC Rogler G Bamias G Breynaert C Florholmen J Pellino G Cellular and molecular mediators of intestinal fibrosis J Crohns Colitis 2014 e-pub ahead of print 8 October 2014; doi: 10.1016/j.crohns.2014.09.008 PMC5885809 25306501
Haydont V Vozenin-Brotons MC Maintenance of radiation-induced intestinal fibrosis: cellular and molecular features World J Gastroenterol 2007 13 2675 2683 17569135 10.3748/wjg.v13.i19.2675 PMC4147115
Yarnold J Brotons MC Pathogenetic mechanisms in radiation fibrosis Radiother Oncol 2010 97 149 161 20888056 10.1016/j.radonc.2010.09.002
Sémont A Francois S Mouiseddine M Francois A Saché A Frick J Mesenchymal stem cells increase self-renewal of small intestinal epithelium and accelerate structural recovery after radiation injury Adv Exp Med Biol 2006 585 19 30 17120774 10.1007/978-0-387-34133-0_2
Sémont A Mouiseddine M Francois A Demarguay C Mathieu N Chapel A Mesenchymal stem cells improve small intestinal integrity though regulation of endogenous epithelial cell homeostasis Cell Death Differ 2010 17 952 961 20019749 10.1038/cdd.2009.187
Kudo K Liu Y Takahashi K Tarusawa K Osanai M Hu DL Transplantation of mesenchymal stem cells to prevent radiation-induced intestinal injury in mice J Radiat Res 2010 51 73 79 19851042 10.1269/jrr.09091
Kudo K Abe Y Hu DL Kijima H Nakane A Colonization and differentiation of transplanted embryonic stem cells in the irradiated intestine of mice Tohoku J Exp Med 2007 212 143 150 17548958 10.1620/tjem.212.143
Saha S Bhanja P Kabarriti R Liu L Alfieri AA Guha C Bone marrow stromal cell transplantation mitigates radiation-induced gastrointestinal syndrome in mice PLoS One 2011 6 e24072 21935373 10.1371/journal.pone.0024072 PMC3174150
Francois M Birman E Forner KA Gaboury L Gallipeau J Adoptive transfer of mesenchymal stromal cells accelerates intestinal epithelium recovery of irradiated mice in an interleukin-6-dependent manner Cytotherapy 2012 14 1164 1170 22574720 10.3109/14653249.2012.684378
Gao Z Zhang Q Han Y Cheng X Lu Y Fan L Mesenchymal stromal cell-conditioned medium prevents radiation-induced small intestine injury in mice Cytotherapy 2012 14 267 273 21958222 10.3109/14653249.2011.616194
Chang P Qu Y Liu Y Cui S Zhu D Wang H Multi-therapeutic effects of human adipose-derived mesenchymal stem cells on radiation-induced intestinal injury Cell Death Dis 2013 4 e685 23788042 10.1038/cddis.2013.178 PMC3698545
Linard C Busson E Holler V Strup-Perrot C Lacave-Lapalun JV Lhomme B Repeated autologous bone marrow-derived mesenchymal stem cell injections improve radiation-induced proctitis in pigs Stem Cells Transl Med 2013 2 916 927 24068742 10.5966/sctm.2013-0030 PMC3808206
Bessout R Sémont A Demarguay C Charcosset A Benderitter M Mathieu N Mesenchymal stem cell therapy induces glucocorticoid synthesis in colonic mucosa and suppresses radiation-activated T cells: new insights into MSC immunomodulation Mucosal Immunol 2014 7 656 669 24172849 10.1038/mi.2013.85
Zong ZW Cheng TM Su YP Ran XZ Shen Y Li N Recruitment of transplanted dermal multipotent stem cells to sites of injury in rats with combined radiation and wound injury by interaction of SDF-1 and CXCR4 Radiat Res 2008 170 444 450 19024651 10.1667/rr0744.1
Ji JF He BP Dheen ST Tay SS Interactions of chemokines and chemokine receptors mediate the migration of mesenchymal stem cells to the impaired site in the brain after hypoglossal never injury Stem Cells 2004 22 415 427 15153618 10.1634/stemcells.22-3-415
Francois S Bensidhoum M Moureseddine M Mazurier C Allenet B Sémont A Local irradiation not only induces homing of human mesenchymal stem cells at exposed sites but promotes their widespread engraftment to multiple organs: a study of their quantitative distribution after irradiation damage Stem Cells 2006 24 1020 1029 16339642 10.1634/stemcells.2005-0260
Zhang J Gong JF Zhang W Zhu WM Li JS Effects of transplated bone marrow mesenchymal stem cells on the irradiated intestine of mice J Biomed Sci 2008 15 585 594 18763056 10.1007/s11373-008-9256-9
Yang C Chen HX Zhou Y Liu MX Wang JX Ren SP Manganese superoxide dismutase gene therapy protects against irradiation-induced intestinal injury Curr Gene Ther 2013 13 305 314 24060314 10.2174/15665232113136660027
Hu J Yang Z Wang J Tang Y Liu H Zhang B Infusion of Trx-1-overexpressing huc MSC prolongs the survival of acutely irradiated NOD/SCID mice by decreasing excessive inflammatory injury PLoS One 2013 8 e78227 24223778 10.1371/journal.pone.0078227 PMC3817237
Zangi L Margalit R Reich-Zeliger S Bachar-Lustig E Beilhack A Negrin R Direct imaging of immune rejection and memory induction by allogeneic mesenchymal stromal cells Stem Cells 2009 27 2865 2874 19750539 10.1002/stem.217
Hu C Yong X Li C Lü M Liu D Chen L CXCL12/CXCR4 axis promotes mesenchymal stem cell mobilization to burn wounds and contributes to wound repair J Surg Res 2013 183 427 434 23462453 10.1016/j.jss.2013.01.019
Ren G Zhao X Zhang L Zhang J L'Huillier A Ling W Inflammatory cytokine-induced intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in mesenchymal stem cells are critical for immunosuppression J Immunol 2010 184 2321 2328 20130212 10.4049/jimmunol.0902023 PMC2881946
Ringe J Strassburg S Neumann K Endres M Notter M Burmester GR Towards in situ tissue repair: human mesenchymal stem cells express chemokine receptors CXCR1, CXCR2 and CCR2, and migrate upon stimulation with CXCL8 but not CCL2 J Cell Biochem 2007 101 135 146 17295203 10.1002/jcb.21172
Paguet-Fifield S Schlüter H Li A Aitken T Gangatirkar P Blashki D A role for pericytes as microenvironmental regulators of human skin tissue regeneration J Clin Invest 2009 119 2795 2806 19652362 10.1172/JCI38535 PMC2735900
Linero I Chaparro O Paracrine effect of mesenchymal stem cells from human adipose tissue in bone regeneration PLoS One 2014 9 e107001 25198551 10.1371/journal.pone.0107001 PMC4157844
Aggarwal S Pittenger MF Human mesenchymal stem cells modulate allogeneic immune cell responses Blood 2005 105 1815 1822 15494428 10.1182/blood-2004-04-1559
Maggini J Mirkin G Bognanni I Holmberg J Piazzón IM Nepomnaschy I Mouse bone marrow-derived mesenchymal stromal cells turn activated macrophages into a regulatory-like profile PLoS One 2010 5 e9252 20169081 10.1371/journal.pone.0009252 PMC2821929
Németh K Leelahavanichkul A Yuen PS Mayer B Parmelee A Doi K Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production Nat Med 2009 15 42 49 19098906 10.1038/nm.1905 PMC2706487
Pils MC Pisano F Fasnacht N Heinrich JM Groebe L Schippers A Monocytes/macrophages and/or neutrophils are the target of IL-10 in the LPS endotoxemia model Eur J Immunol 2010 40 443 448 19941312 10.1002/eji.200939592
Spaggiari GM Abdelrazik H Becchetti F Moretta L MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2 Blood 2009 113 6576 6583 19398717 10.1182/blood-2009-02-203943
Spaggiari GM Capobianco A Abdelrazik H Becchetti F Mingari MC Moretta L Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2 Blood 2008 111 1327 1333 17951526 10.1182/blood-2007-02-074997
Selmani Z Naji A Zidi I Favier B Gaiffe E Borg C Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells Stem Cells 2008 26 212 222 17932417 10.1634/stemcells.2007-0554
Hsu WT Lin CH Chiang BL Jui HY Wu KK Lee CM Prostaglandin E2 potentiates mesenchymal stem cell-induced IL-10+IFN-γ+CD4+ regulatory T cells to control transplant arteriosclerosis J Immunol 2013 190 2372 2380 23359497 10.4049/jimmunol.1202996
Gonzalez-Rey E Anderson P González MA Rico L Büscher D Delgado M Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis Gut 2009 58 929 939 19136511 10.1136/gut.2008.168534
Parekkadan B Upadhyay R Dunham J Iwamoto Y Mizoguchi E Mizoguchi A Bone marrow stromal cell transplants prevent experimental enterocolitis and require host CD11b+ splenocytes Gastroenterology 2011 140 966 975 20955701 10.1053/j.gastro.2010.10.013 PMC3033974
Brown JM Nemeth K Kushnir-Sukhov NM Metcalfe DD Mezey E Bone marrow stromal cells inhibit mast cell function via a COX2-dependent mechanism Clin Exp Allergy 2011 41 526 534 21255158 10.1111/j.1365-2222.2010.03685.x PMC3078050
Kim HS Yun JW Shin TH Lee SH Lee BC Yu KR Human umbilical cord blood mesenchymal stem cell-derived PGE2 and TGF- β 1 Alleviate atopic dermatitis by reducing mast cell degranulation Stem Cells 2015 33 1254 1266 25522163 10.1002/stem.1913
Lombard E van der Poll T DelaRosa O Dalemans W Mesenchymal stem cells as a therapeutic tool to treat sepsis World J Stem Cells 2015 7 368 379 25815121 10.4252/wjsc.v7.i2.368 PMC4369493
Meisel R Brockers S Heseler K Degistirici O Bülle H Woite C Human but not murine multipotent mesenchymal stromal cells exhibit broad-spectrum antimicrobial effector function mediated by indoleamine 2,3-dioxygenase Leukemia 2011 25 648 654 21242993 10.1038/leu.2010.310
Krasnodembskaya A Samarani G Song Y Zhou H Su X Lee JW Human mesenchymal stem cells reduce mortality and bacteremia in gram-negative sepsis in mice in part by enhancing the phagocytic activity of blood monocytes Am J Physiol Lung Cell Mol Physiol 2012 302 L1003 L1013 22427530 10.1152/ajplung.00180.2011 PMC3362255
Krasnodembskaya A Song Y Fang X Gupta N Serikov V Lee JW Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37 Stem Cells 2010 28 2229 2238 20945332 10.1002/stem.544 PMC3293245
Chang W Song BW Moon JY Cha MJ Ham O Lee SY Anti-death strategies against oxidative stress in grafted mesenchymal stem cells Histol Histopathol 2013 28 1529 1536 23760682 10.14670/HH-28.1529
Lange C Brunswig-Spickenheier B Cappallo-Obermann H Eggert K Gehling UM Rudolph C Radiation rescue: mesenchymal stromal cells protect from lethal irradiation PLoS One 2011 6 e14486 21245929 10.1371/journal.pone.0014486 PMC3016319
Brittan M Chance V Elia G Poulsom R Alison MR MacDonald TT A regenerative role for bone marrow following experimental colitis: contribution to neovasculogenesis and myofibroblasts Gastroenterology 2005 128 1984 1995 15940631 10.1053/j.gastro.2005.03.028
Okamoto R Yajima T Yamazaki M Kanai T Mukai M Okamoto S Damaged epithelial regenerated by bone marrow-derived cells in the human gastrointestinal tract Nat Med 2002 8 1011 1017 12195435 10.1038/nm755
Guan A Gong H Ye Y Jia J Zhang G Li B Regulation of p53 by jagged 1 contributes to angiotensin II-induced impairment of myocardial angiogenesis PLoS One 2013 8 e76529 24098521 10.1371/journal.pone.0076529 PMC3789680
Demidov ON Timofeev O Lwin HN Kek C Appella E Bulavin DV Wip1 phosphatase regulates p53-dependent apoptosis of stem cells and tumorigenesis in the mouse intestine Cell Stem Cell 2007 1 180 190 18371349 10.1016/j.stem.2007.05.020
John S Mesenchymal stem cells in cancer Stem Cell Rev 2008 4 119 124 18493880 10.1007/s12015-008-9030-4
Kuhn NZ Tuan RS Regulation of stemness and stem cell niche of mesenchymal stem cells: implications in tumorigenesis and metastasis J Cell Physiol 2010 222 268 277 19847802 10.1002/jcp.21940
Han Z Jing Y Zhang S Liu Y Shi Y Wei L The role of immunesuppression of mesenchymal stem cells in tissue repair and tumor growth Cell Biosci 2012 2 8 22390479 10.1186/2045-3701-2-8 PMC3315743
Røsland GV Svendsen A Torsvik A Sobala E Mc Cormack E Immervoll H Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation Cancer Res 2009 69 5331 5339 19509230 10.1158/0008-5472.CAN-08-4630
Burns JS Abdallah BM Guldberg P Rygaard J Schrøder HD Kassem M Tumorigenic heterogeneity in cancer stem cells evolved from long-term cultures of telomerase-immortalized human mesenchymal stem cells Cancer Res 2005 65 3126 3135 15833842 10.1158/0008-5472.CAN-04-2218
Rubio D Garcia-Castro J Martín MC de la Fuente R Cigudosa JC Lloyd AC Spontaneous human adult stem cell transformation Cancer Res 2005 65 3035 3039 15833829 10.1158/0008-5472.CAN-04-4194
Li H Fan X Kovi RC Jo Y Moguin B Konz R Spontaneous expression of embryonic factors and p53 point mutations in aged mesenchymal stem cells: a model of age-related tumorigenesis in mice Cancer Res 2007 67 10889 10898 18006834 10.1158/0008-5472.CAN-07-2665
Rodriguez R Rubio R Masip M Catalina P Nieto A de la Cueva T Loss of p53 induces tumorigenesis in p21-deficient mesenchymal stem cells Neoplasia 2009 11 397 407 19308294 10.1593/neo.81620 PMC2657886
Bernardo ME Zaffaroni N Novara F Cometa AM Avanzini MA Moretta A Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms Cancer Res 2007 67 9142 9149 17909019 10.1158/0008-5472.CAN-06-4690
Choumerianou DM Dimitriou H Perdikogianni C Martimianaki G Riminucci M Kalmanti M Study of oncogenic transformation in ex vivo expanded mesenchymal cells, from paediatric bone marrow Cell Prolif 2008 41 909 922 19040569 10.1111/j.1365-2184.2008.00559.x PMC6496314
Zimmerlin L Park TS Zambidis ET Donnenberg VS Donnenberg AD Mesenchymal stem cell secretome and regenerative therapy after cancer Biochimie 2013 95 2235 2245 23747841 10.1016/j.biochi.2013.05.010 PMC3825748
Khakoo AY Pati S Anderson SA Reid W Elshal MF Rovira II Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma J Exp Med 2006 203 1235 1247 16636132 10.1084/jem.20051921 PMC2121206
Li X Ling W Pennisi A Wang Y Khan S Heidaran M Human placenta-derived adherent cells prevent bone loss, stimulate bone formation, and suppress growth of multiple myeloma in bone Stem Cells 2011 29 263 273 21732484 10.1002/stem.572 PMC3175303
Ahn JO Coh YR Lee HW Shin IS Kang SK Youn HY Human adipose tissue-derived mesenchymal stem cells inhibit melanoma growth in vitro and in vivo Anticancer Res 2015 35 159 168 25550547
Nasuno M Arimura Y Nagaishi K Isshiki H Onodera K Nakagaki S Mesenchymal stem cells cancel azoxymethane-induced tumor initiation Stem Cells 2014 32 913 925 24715689 10.1002/stem.1594
Katsuno T Ochi M Tominaga K Tanaka F Sogawa M Tanigawa T Mesenchymal stem cells administrated in the early phase of tumorigenesis inhibit colorectal tumor development in rats J Clin Biochem Nutr 2013 53 170 175 24249972 10.3164/jcbn.13-68 PMC3818273
Lu YR Yuan Y Wang XJ Wei LL Chen YN Cong C The growth inhibitory effect of mesenchymal stem cells on tumor cells in vitro and in vivo Cancer Biol Ther 2008 7 245 251 18059192 10.4161/cbt.7.2.5296
Qiao L Xu Z Zhao T Zhao Z Shi M Zhao RC Suppression of tumorigenesis by human mesenchymal stem cells in a hepatoma model Cell Res 2008 18 500 507 18364678 10.1038/cr.2008.40
Abd-Allah SH Shalaby SM El-Shai AS Elkader EA Hussein S Emam E Effect of bone marrow-derived mesenchymal stromal cells on hepatoma Cytotherapy 2014 16 1197 1206 24985939 10.1016/j.jcyt.2014.05.006
Ahn JO Chae JS Coh YR Jung WS Lee HW Shin IS Human adipose tissue-derived mesenchymal stem cells inhibit T-cell lymphoma growth in vitro and in vivo Anticancer Res 2014 34 4839 4847 25202065
Chien LY Hsiao JK Hsu SC Yao M Lu CW Liu HM In vivo magnetic resonance imaging of cell tropism, trafficking mechanism, and therapeutic impact of human mesenchymal stem cells in a murine glioma model Biomaterials 2011 32 3275 3284 21295344 10.1016/j.biomaterials.2011.01.042
Vegh I Grau M Gracia M Grande J de la Torre P Flores AI Decidua mesenchymal stem cells migrated toward mammary tumors in vitro and in vivo affecting tumor growth and tumor development Cancer Gene Ther 2013 20 8 16 23037810 10.1038/cgt.2012.71
Abdel aziz MT EI Asmar MF Atta HM Mahfouz S Fouad HH Roshdy NK Efficacy of mesenchymal stem cells in suppression of hepatocarcinorigenesis in rats: possible role of Wnt signaling J Exp Clin Cancer Res 2011 30 49 21545718 10.1186/1756-9966-30-49 PMC3113743
Ma Y Hao X Zhang S Zhang J The in vitro and in vivo effects of human umbilical cord mesenchymal stem cells on the growth of breast cancer cells Breast Cancer Res Treat 2012 133 473 485 21947651 10.1007/s10549-011-1774-x
Zhu Y Sun Z Han Q Liao L Wang J Bian C Human mesenchymal stem cells inhibit cancer cell proliferation by secreting DKK-1 Leukemia 2009 23 925 933 19148141 10.1038/leu.2008.384
Lee RH Kim B Choi I Kim H Choi HS Suh K Characterization and expression analysis of mesenchymal stem cells from human bone marrow and adipose tissue Cell Physiol Biochem 2004 14 311 324 15319535 10.1159/000080341
Fodde R Brabletz T Wnt/beta-catenin signaling in cancer stemness and malignant behavior Curr Opin Cell Biol 2007 19 150 158 17306971 10.1016/j.ceb.2007.02.007
Han I Yun M Kim EO Kim B Jung MH Kim SH Umbilical cord tissue-derived mesenchymal stem cells induce aoptosis in PC-3 prostate cancer cells through activation of JNK and downregulation of PI3K/Akt signaling Stem Cell Res Ther 2014 5 54 24739733 10.1186/scrt443 PMC4055109
Xiang J Tang J Song C Yang Z Hirst DG Zheng QJ Mesenchymal stem cells as a gene therapy carrier for treatment of fibrosarcoma Cytotherapy 2009 11 516 526 19562576 10.1080/14653240902960429
Nakamura K Ito Y Kawano Y Kurozumi K Kobune M Tsuda H Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model Gene Ther 2004 11 1155 1164 15141157 10.1038/sj.gt.3302276
Gao P Ding Q Wu Z Jiang H Fang Z Therapeutic potential of human mesenchymal stem cells producing IL-12 in a mouse xenograft model of renal cell carcinoma Cancer Lett 2010 290 157 166 19786319 10.1016/j.canlet.2009.08.031
Chapel A Francois S Douay L Benderitter M Voswinkel J Fifteen years of preclinical and clinical experiences about biotherapy treatment of lesions induced by accidental irradiation and radiotherapy World J Stem Cells 2013 5 68 72 23951388 10.4252/wjsc.v5.i3.68 PMC3744132
Bernardo ME Fibbe WE Safety and efficacy of mesenchymal stromal cell therapy in autoimmune disorders Ann NY Acad Sci 2012 1266 107 117 22901262 10.1111/j.1749-6632.2012.06667.x
Robey PG Kuznetsov SA Ren J Klein HG Sabatino M Stroncek DF Generation of clinical grade human bone marrow stromal cells for use in bone regeneration Bone 2015 70 87 92 25064527 10.1016/j.bone.2014.07.020 PMC4268331
Lai RC Yeo RW Lim SK Mesenchymal stem cell exosomes Semin Cell Dev Biol 2015 40 82 88 25765629 10.1016/j.semcdb.2015.03.001
Sokolova V Ludwig AK Hornung S Rotan O Horn PA Epple M Characterisation of exosomes derived from human cells by nanoparticle tracking analysis and scanning electron microscopy Colloids Surf B Biointerfaces 2011 87 146 150 21640565 10.1016/j.colsurfb.2011.05.013
Berardis S Dwisthi Sattwika P Najimi M Sokal EM Use of mesenchymal stem cells to treat liver fibrosis: Current situation and future prospects World J Gastroenterol 2015 21 742 758 25624709 10.3748/wjg.v21.i3.742 PMC4299328
Ohmori K Masuda K DeBoer DJ Sakaguchi M Tsujimoto H Immunoblot analysis for IgE-reactive components of fetal calf serum in dogs that developed allergic reactions after non-rabies vaccination Vet Immunol Immunopathol 2007 115 166 171 17118462 10.1016/j.vetimm.2006.10.005 PMC7112532
Abbott A Leaked files slam stem-cell therapy Nature 2014 505 139 140 24402259 10.1038/505139a
Salem HK Thiemermann C Mesenchymal stromal cells: current understanding and clinical status Stem Cells 2010 28 585 596 19967788 10.1002/stem.269 PMC2962904
Lodi D Iannitti T Palmieri B Stem cells in clinical practice: applications and warnings J Exp Clin Cancer Res 2011 30 9 21241480 10.1186/1756-9966-30-9 PMC3033847